Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uday B Dandamudi

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
American Journal of Translational Research|August 25, 2010
Warfarin genotyping using three different platformsJoel A Lefferts, Mary C Schwab, Uday B Dandamudi, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancerGeoffrey I Shapiro, Richard Frank, Uday B Dandamudi, et al.
Journal of Chemotherapy (Florence, Italy)|October 8, 2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumoursShodeinde A Coker, Uday B Dandamudi, Andrew P Beelen, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2010
Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancerUday B Dandamudi, Laurel M Adams, Brendan Johnson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
American Journal of Translational Research|August 25, 2010
Warfarin genotyping using three different platformsJoel A Lefferts, Mary C Schwab, Uday B Dandamudi, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancerGeoffrey I Shapiro, Richard Frank, Uday B Dandamudi, et al.
Journal of Chemotherapy (Florence, Italy)|October 8, 2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumoursShodeinde A Coker, Uday B Dandamudi, Andrew P Beelen, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2010
Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancerUday B Dandamudi, Laurel M Adams, Brendan Johnson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Pageof 1